DAIICHI SANKYO, INC.

Daiichi Sankyo and AstraZeneca awarded 2024 Prix Galien USA for ENHERTU, a HER2-directed ADC, at American Museum of Natural History in New York.

Alteogen signed an exclusive license agreement with Daiichi Sankyo to develop and commercialize a subcutaneous version of Enhertu, an ADC cancer treatment, using Alteogen’s ALT-B4 technology. Daiichi Sankyo will pay $20 million upfront and up to $280 million in additional payments based on milestones, with royalties on net sales. This marks the first global attempt to convert ADCs into subcutaneous formulations, potentially reducing side effects and improving efficacy.

Antibody drug conjugates (ADCs) are a transformative class in cancer treatment, with 16 approved products and sales exceeding $10B in 2023. The market is expected to surpass $50B by 2030, driven by over 500 ADCs in clinical trials. Key players include Enhertu, Kadcyla, and Padcev, with significant sales in breast and lung cancers. The US and China lead the market, supported by robust R&D and regulatory environments.

FDA approves Caris Life Sciences' MI Cancer Seek as companion diagnostic for multiple cancer drugs across six cancer types, including solid tumours, breast cancer, colorectal cancer, melanoma, non-small cell lung cancer, and endometrial carcinoma. The assay uses whole exome sequencing (WES) and whole transcriptome sequencing (WTS) for molecular profiling of solid tumours.

Tendinopathy market poised for growth due to increasing prevalence, awareness, and emerging treatments by companies like MiMedx, Novartis, Ipsen, and others. Key therapies include secukinumab, PRP, MSCs, corticosteroids, nitroglycerin patches, BPC-157, collagen hydrolysate, and hyaluronic acid. Market drivers include aging populations, sports participation, biologics advancements, and early diagnosis. Barriers include high therapy costs, limited awareness in developing countries, lack of standardized protocols, and competing therapies.